Apollomics Inc. (APLM)
APLM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1944885/000119312526177357/0001193125-26-177357-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | APLM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001944885 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8.5M |
| Net income | -$10.9M |
| Operating income | Not in SEC XBRL data |
| Net margin | -128.7% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $3.3M |
| Total assets | $6.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 20-F 2026-04-24 |
| Cash and burn | $3.3M cash; operating cash flow -$2.6M a quarter. | Report 2025-12-31 |
| Shares outstanding | 2,196,052 (2026-04-24); 1,103,348 a year earlier. the newest SEC cover-page count is from 2026-04-24; shares issued since then are not in these figures. | Cover page 2026-04-24 |
| Reverse splits, 3 years | 1; latest 1-for-100 on 2024-11-25 | Source 2024-11-25 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-09 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Marcum Asia CPAs LLP, New York, New York, United States | PCAOB Form AP 2026-04-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $8.3M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $8.5M | -$10.9M | -$10.4M | $3.3M | $0 | $8.5M | 20-F 2026-04-24 |
| FY 2024 2024-12-31 | $0 | -$53.9M | -$28.7M | $9.8M | $0 | $0 | 20-F 2025-04-03 |
| FY 2023 2023-12-31 | $0 | -$172.6M | -$43.2M | $32.1M | $4.2M | $0 | 20-F 2025-04-03 |
| FY 2022 2022-12-31 | $0 | -$240.8M | -$42.8M | $32.7M | No debt tags | $0 | 20-F 2025-04-03 |
| FY 2021 2021-12-31 | $0 | -$94.8M | -$43.3M | $46.7M | No debt tags | $0 | 20-F 2024-03-28 |
| FY 2020 2020-12-31 | $0 | -$74.8M | -$35.7M | $130.6M | No debt tags | $0 | 20-F 2023-04-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-08 |
| Latest annual report | 20-F | 2026-04-24 |
| Latest quarterly / interim | 6-K | 2026-11-06 |
Source: SEC EDGAR submissions feed, 184 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.9% |
| 1 month | -17.1% |
| 3 months | +1.8% |
| Year to date | -5.4% |
| 1 year | -15.6% |
| From 52-week high | -36.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| APLMW | Apollomics Inc. Warrant | $0.0105 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SDEV | Stablecoin Development Corporation | $0.7055 | -9.55% | $51.6M |
| QUCY | Quantum Cyber N.V. | $0.5850 | -7.58% | $51.0M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
| RFL | Rafael Holdings Inc. | $0.9701 | -9.34% | $50.6M |
| IBIO | iBio Inc. | $0.7067 | -3.42% | $49.8M |
| CTOR | Citius Oncology Inc. | $0.5350 | -6.76% | $49.7M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier